Blog

COMPASS Pathways

Press

COMPASS Pathways plc to announce second quarter 2021 financial results on 11 August 2021

Quick Take: Compass Pathways will announce their second quarter financial results on August 11. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2021, and provide an update on recent business developments, on 11 August 2021. The management team will host a conference call at 1:00pm UK (8.00am ET) on 11 August. The call can be accessed by dialing (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK,…

Pharmadrug

Press

PharmaDrug Forms Research Collaboration with Terasaki Institute for Novel Ocular Drug Formulation Program to Deliver DMT and Other Tryptamines to Treat Eye Disease

Quick Take: PharmaDrug has formed a partnership with a biotechnology institute to research DMT therapy for eye diseases. PharmaDrug Inc. (CSE: PHRX), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that PharmaDrug has entered into a sponsored research agreement with the Terasaki Institute to develop a novel ocular drug delivery platform that aims to deliver psychedelic and tryptamine-based pharmaceuticals, such as N, N-dimethyltryptamine (“DMT”), for eye diseases. PharmaDrug will focus on developing a novel ocular drug delivery platform to deliver…

Cybin

Press

Cybin to Commence Trading on the NYSE American on August 5

Quick Take: Cybin will begin trading on the NYSE today under the ticker “CYBN” Cybin Inc. (NEO:CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its common shares will open for trading on the NYSE American LLC stock exchange (“NYSE American”)on August 5, 2021, under the symbol “CYBN”.   In addition to listing and trading on the NYSE American in U.S. dollars, Cybin’s common shares will continue to be listed and trade in Canada on the NEO Exchange (“NEO”) in Canadian dollars under the symbol “CYBN”. Shareholders that purchased their Cybin common shares “over-the-counter” or OTC, including shareholders…

Awakn life sciences

Press

Awakn Life Sciences Announces Its Second Location in the UK for “Awakn Clinics London,” Providing Treatment to the Largest City in the UK

Quick Take: Awakn has announced its plans to open a psychedelic treatment clinic in the city of London. Awakn Life Sciences Corp. (NEO: AWKN), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions. Awakn Clinics London, a 5,000 square-foot, 8 treatment room clinic, will deliver psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies. The clinic launch is a response to the growing global population suffering from Addiction, including alcohol and…

Tryp Therapeutics

Press

Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Quick Take: Tryp Therapeutics is slated to present at the Canaccord Genuity Annual Growth Conference. Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference. The conference will be held virtually on August 10-12, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program for chronic pain and eating disorder indications. Details for the presentation are as follows: When: Tuesday, August 10thTime:…